NASDAQ:GRFS Grifols (GRFS) Stock Price, News & Analysis $7.54 +0.30 (+4.14%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$7.58 +0.04 (+0.53%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Grifols Stock (NASDAQ:GRFS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Grifols alerts:Sign Up Key Stats Today's Range$7.40▼$7.5650-Day Range$7.17▼$8.2552-Week Range$6.96▼$9.90Volume907,078 shsAverage Volume628,428 shsMarket Capitalization$5.13 billionP/E Ratio39.68Dividend Yield1.19%Price Target$10.00Consensus RatingReduce Company Overview Grifols S.A. is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products. Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines. Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing. In addition, the company offers hospital pharmacy products and services. Its operations and products serve healthcare providers and patients in numerous markets across North America, Europe and other international regions.AI Generated. May Contain Errors. Read More Grifols Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreGRFS MarketRank™: 4.24996716143 of 5 starsGrifols scored higher than 85% of companies evaluated by MarketBeat, and ranked 64th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingGrifols has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialGrifols has a consensus price target of $10.00, representing about 32.6% upside from its current price of $7.54.Amount of Analyst CoverageGrifols has only been the subject of 1 research reports in the past 90 days.Read more about Grifols' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth24.07% Earnings GrowthEarnings for Grifols are expected to grow by 24.07% in the coming year, from $1.08 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Grifols is 39.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 35.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Grifols is 39.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 206.61.Price to Earnings Growth RatioGrifols has a PEG Ratio of 0.27. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioGrifols has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Grifols' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.03% of the float of Grifols has been sold short.Short Interest Ratio / Days to CoverGrifols has a short interest ratio ("days to cover") of 8.66.Change versus previous monthShort interest in Grifols has recently increased by 105.05%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldGrifols pays a meaningful dividend of 1.18%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGrifols does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Grifols is 47.37%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Grifols will have a dividend payout ratio of 6.72% next year. This indicates that Grifols will be able to sustain or increase its dividend.Read more about Grifols' dividend. News and Social Media2.1 / 5News Sentiment0.32 News SentimentGrifols has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Grifols this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Grifols to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grifols insiders have not sold or bought any company stock.Percentage Held by Insiders0.19% of the stock of Grifols is held by insiders.Percentage Held by InstitutionsGrifols has minimal institutional ownership at this time.Read more about Grifols' insider trading history. Receive GRFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRFS Stock News HeadlinesBridgeBio Pharma (NASDAQ:BBIO) versus Grifols (NASDAQ:GRFS) Head-To-Head AnalysisOctober 12, 2026 | americanbankingnews.comGrifols (NASDAQ:GRFS) Stock Rating Cut to "Hold" at Wall Street ZenOctober 10, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 16 at 1:00 AM | Behind the Markets (Ad)Are options traders betting on a big move in Grifols stock?October 8, 2026 | msn.comGrifols says Canada plasma license suspension has no impactSeptember 24, 2026 | reuters.comGRFS - Grifols, S.A.September 17, 2026 | seekingalpha.comGrifols: Better Plasma Economics Can Unlock A Discounted EquitySeptember 16, 2026 | seekingalpha.comGrifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin DeficiencyAugust 10, 2026 | markets.businessinsider.comSee More Headlines GRFS Stock Analysis - Frequently Asked Questions How have GRFS shares performed this year? Grifols' stock was trading at $9.35 at the beginning of the year. Since then, GRFS shares have decreased by 19.4% and is now trading at $7.54. How were Grifols' earnings last quarter? Grifols, S.A. (NASDAQ:GRFS) issued its earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter. Grifols had a trailing twelve-month return on equity of 6.21% and a net margin of 5.54%. When did Grifols' stock split? Shares of Grifols split on the morning of Monday, January 4th 2016.The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Grifols have any subsidiaries? Grifols subsidiaries include Biotest US Corporation, Haema AG, Goetech LLC (D/B/A Medkeeper), Kiro Robotics, Progenika Biopharma, Araclon Biotech, Talecris Biotherapeutics, and more. Who are Grifols' major shareholders? Grifols' top institutional shareholders include Financial Symmetry Inc, GAMMA Investing LLC and Versant Capital Management Inc. How do I buy shares of Grifols? Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Grifols own? Based on aggregate information from My MarketBeat watchlists, some other companies that Grifols investors own include Immunovant (IMVT), NVIDIA (NVDA), Tesla (TSLA), Boeing (BA), Gilead Sciences (GILD), ExxonMobil (XOM) and Intel (INTC). Company Calendar Last Earnings5/04/2021Today10/16/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GRFS's financial health is in the Yellow zone, according to TradeSmith. GRFS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GRFS CIK1438569 Webwww.grifols.com Phone(493) 571-0221Fax34-93-571-0267Employees25,247Year Founded1909Price Target and Rating Average Price Target for Grifols$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+32.6%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.19 Trailing P/E Ratio39.68 Forward P/E Ratio6.98 P/E Growth0.27Net Income$454.82 million Net Margins5.54% Pretax Margin8.18% Return on Equity6.21% Return on Assets2.39% Debt Debt-to-Equity Ratio1.10 Current Ratio2.37 Quick Ratio0.81 Sales & Book Value Annual Sales$8.51 billion Price / Sales0.60 Cash Flow$1.48 per share Price / Cash Flow5.11 Book Value$12.64 per share Price / Book0.60Miscellaneous Outstanding Shares680,580,000Free Float679,282,000Market Cap$5.13 billion OptionableOptionable Beta0.70 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GRFS) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
